Affymetrix released earnings Wednesday night. [Conference call transcript here]
Last week the specialized biotech supplier announced a genotyping collaboration with Kaiser Permanente and the University of California. Short sellers have been active, building a position which currently stands at 4.5% of the shares outstanding, and the short base has been rising for a number of weeks. Utilization of lender inventory stands at around 10%.
To download the whole article click here.